Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

477 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Patient needs and point-of-care requirements for HIV load testing in resource-limited settings.
Usdin M, Guillerm M, Calmy A. Usdin M, et al. J Infect Dis. 2010 Apr 15;201 Suppl 1:S73-7. doi: 10.1086/650384. J Infect Dis. 2010. PMID: 20225951 Review.
We hope that, by clearly defining the needs of patients in MSF clinics-as well as we can assess this-and by explaining why these tools are needed, how they should perform, and how their results can be integrated into a program, we will encourage the development of such too …
We hope that, by clearly defining the needs of patients in MSF clinics-as well as we can assess this-and by explaining why these tools are n …
Mean CD4 cell count changes in patients failing a first-line antiretroviral therapy in resource-limited settings.
Calmy A, Balestre E, Bonnet F, Boulle A, Sprinz E, Wood R, Delaporte E, Messou E, McIntyre J, El Filali KM, Schechter M, Kumarasamy N, Bangsberg D, McPhail P, Van Der Borght S, Zala C, Egger M, Thiébaut R, Dabis F; T-LINC of IeDEA Collaboration (Asia, South America, East, Southern and West Africa). Calmy A, et al. BMC Infect Dis. 2012 Jun 28;12:147. doi: 10.1186/1471-2334-12-147. BMC Infect Dis. 2012. PMID: 22742573 Free PMC article.
RESULTS: 3,338 patients were included (14 cohorts, 64% female) and the group had the following characteristics: a median follow-up time of 1.6 years, a median age of 34 years, and a median CD4 cell count at ART initiation of 107 cells/μL. ...By contrast, any …
RESULTS: 3,338 patients were included (14 cohorts, 64% female) and the group had the following characteristics: a median follow-up ti …
The Interplay Between Host Genetic Variation, Viral Replication, and Microbial Translocation in Untreated HIV-Infected Individuals.
Perkins MR, Bartha I, Timmer JK, Liebner JC, Wolinsky D, Günthard HF, Hauser C, Bernasconi E, Hoffmann M, Calmy A, Battegay M, Telenti A, Douek DC, Fellay J; Swiss HIV Cohort Study. Perkins MR, et al. J Infect Dis. 2015 Aug 15;212(4):578-84. doi: 10.1093/infdis/jiv089. Epub 2015 Feb 20. J Infect Dis. 2015. PMID: 25701868 Free PMC article.
Systemic immune activation, a major determinant of human immunodeficiency virus (HIV) disease progression, is the result of a complex interplay between viral replication, dysregulation of the immune system, and microbial translocation due to gut mucosal damage. ...U …
Systemic immune activation, a major determinant of human immunodeficiency virus (HIV) disease progression, is the result of a
Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection.
Neuhaus J, Jacobs DR Jr, Baker JV, Calmy A, Duprez D, La Rosa A, Kuller LH, Pett SL, Ristola M, Ross MJ, Shlipak MG, Tracy R, Neaton JD. Neuhaus J, et al. J Infect Dis. 2010 Jun 15;201(12):1788-95. doi: 10.1086/652749. J Infect Dis. 2010. PMID: 20446848 Free PMC article.
Immunovirological response to triple nucleotide reverse-transcriptase inhibitors and ritonavir-boosted protease inhibitors in treatment-naive HIV-2-infected patients: The ACHIEV2E Collaboration Study Group.
Benard A, van Sighem A, Taieb A, Valadas E, Ruelle J, Soriano V, Calmy A, Balotta C, Damond F, Brun-Vezinet F, Chene G, Matheron S; ACHIEV2E Collaboration Study Group. Benard A, et al. Clin Infect Dis. 2011 May;52(10):1257-66. doi: 10.1093/cid/cir123. Clin Infect Dis. 2011. PMID: 21507923
Piecewise linear models were used to estimate CD4 cell count and plasma HIV-2 RNA level slopes, differentiating an early phase (until end of month 3) and a second phase (months 4-12). ...
Piecewise linear models were used to estimate CD4 cell count and plasma HIV-2 RNA level slopes, differentiating an early phase (until end of …
Low bone mineral density, renal dysfunction, and fracture risk in HIV infection: a cross-sectional study.
Calmy A, Fux CA, Norris R, Vallier N, Delhumeau C, Samaras K, Hesse K, Hirschel B, Cooper DA, Carr A. Calmy A, et al. J Infect Dis. 2009 Dec 1;200(11):1746-54. doi: 10.1086/644785. J Infect Dis. 2009. PMID: 19874178
RESULTS: We studied 153 adults (98% men; median age, 48 years; median body mass index, 24.5; 67 [44%] were receiving tenofovir, 81 [53%] were receiving a boosted protease inhibitor [PI]). ...
RESULTS: We studied 153 adults (98% men; median age, 48 years; median body mass index, 24.5; 67 [44%] were receiving tenofovir, 81 [53%] wer …
How developing world concerns need to be part of drug development plans: a case study of four emerging antiretrovirals.
van Roey J, von Schoen-Angerer T, Ford N, Calmy A. van Roey J, et al. Drug Discov Today. 2008 Jul;13(13-14):601-5. doi: 10.1016/j.drudis.2008.04.009. Epub 2008 Jun 17. Drug Discov Today. 2008. PMID: 18598916 Review.
However, a number of issues could limit their use in developing countries, including dose selection, treatment strategy, combination with other drugs, use in specific populations and reliance on expensive tests. ...
However, a number of issues could limit their use in developing countries, including dose selection, treatment strategy, combination …
Successful Prevention of Transmission of Integrase Resistance in the Swiss HIV Cohort Study.
Scherrer AU, Yang WL, Kouyos RD, Böni J, Yerly S, Klimkait T, Aubert V, Cavassini M, Battegay M, Hauser C, Calmy A, Schmid P, Bernasconi E, Günthard HF; Swiss HIV Cohort Study. Scherrer AU, et al. J Infect Dis. 2016 Aug 1;214(3):399-402. doi: 10.1093/infdis/jiw165. Epub 2016 Apr 29. J Infect Dis. 2016. PMID: 27130429
In 1 of 1316 drug-naive samples (0.1%), a major INSTI TDR mutation was detected. Prevalence was stable, although INSTIs were increasingly used. ...We demonstrated on a population-level that it is possible to avoid TDR to a new drug class for years....
In 1 of 1316 drug-naive samples (0.1%), a major INSTI TDR mutation was detected. Prevalence was stable, although INSTIs were increasi …
Origin of minority drug-resistant HIV-1 variants in primary HIV-1 infection.
Metzner KJ, Scherrer AU, Preiswerk B, Joos B, von Wyl V, Leemann C, Rieder P, Braun D, Grube C, Kuster H, Böni J, Yerly S, Klimkait T, Aubert V, Furrer H, Battegay M, Vernazza PL, Cavassini M, Calmy A, Bernasconi E, Weber R, Günthard HF; Swiss HIV Cohort Study. Metzner KJ, et al. J Infect Dis. 2013 Oct 1;208(7):1102-12. doi: 10.1093/infdis/jit310. Epub 2013 Jul 11. J Infect Dis. 2013. PMID: 23847055
477 results
Jump to page
Feedback